Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cumberland Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written Informed Consent and appropriate privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable)
Subject is euvolemic or hypervolemic (edematous) secondary to cirrhosis
Subject has clinical evidence of portal hypertension by the presence of esophageal varices, ascites or both
You may not be if
Clinical evidence of volume depletion or dehydration
Subject has a history of bleeding from esophageal varices within three months before the start of the study
Clareo Health | A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
